Skip to content

Advertisement

  • Poster presentation
  • Open Access

Impact of CMV infection on horizontally transmitted HIV-1 disease progression

  • 1,
  • 1,
  • 1,
  • 2,
  • 2,
  • 1 and
  • 2
Journal of the International AIDS Society200811 (Suppl 1) :P257

https://doi.org/10.1186/1758-2652-11-S1-P257

  • Published:

Keywords

  • Clinical Record
  • Sizeable Number
  • Gender Ratio
  • Fast Progression
  • Dual Infection

Purpose of the study

To evaluate the impact of infection due to cytomegalovirus (CMV) on the clinical evolution and immunological profile of HIV-1 infection horizontally transmitted.

Methods

Retrospective study (January 1997 – December 2007) based on clinical records of HIV-infected patients (pts), following antiretroviral treatment (ART), under surveillance of HIV/AIDS Regional Center, Craiova, Romania. Group A – 32 pts (all pts HIV+, CMV+) has been compared with control group B – 32 pts (HIV+, CMV-); pts have been clinically examined (monthly) and biologically evaluated (quarterly).

Summary of results

Characteristics of group A vs. B follow: average age 22.4 vs. 21.6 years; urban/rural ratio 0.4 vs. 2.2; gender ratio (male/female) 1.7 vs. 1.5; average duration of monitoring 6.8 vs. 7.1 years. There were 1,378 HIV- and/or AIDS-associated clinical events in group A vs. 879 in group B (p = 0.049), and the average number of clinical event/pt/year was 7.3 for the first group vs. 3.8 for the control group. Twenty-five pts (78.1%) from group A have had AIDS-related conditions vs. 10 pts (31.2%) in group B (p = 0.04). Duration from diagnosis to AIDS stage has been 19.1 months in group A vs. 49.5 months in group B (p = 0.01). For a similar number of CD4 lymphocytes, there was a greater basal average CD8 percent in group A (83.2%) vs. B (61.4%) and no significant differences have been noted after 12 months of ART. We have recorded eight deaths; seven from group A and one from group B.

Conclusion

In comparison with pts non-infected with CMV, those with dual infection (HIV+, CMV+) had a sizeable number of HIV/AIDS associated clinical conditions and a faster progression probably due to immunological suppression added by the herpetic infection.

Authors’ Affiliations

(1)
University of Medicine and Pharmacy, Craiova, Romania
(2)
"Victor Babes" Hospital of Infectious Diseases and Pneumology, Craiova, Romania

Copyright

© Cupsa et al; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd.

Advertisement